Startups
Relocated back to its roots in Wilmington, NC in 2018 – TranS1 is a pioneer in spine technology innovation and is focused on Building Better Pathways™ to the spine. Since its inception, TranS1 has designed, developed, and commercialized transformational approaches to the spine used by thousands of surgeons to minimize the damage associated with traditional surgical approaches. TranS1 believes that the process of Building Better Pathways™ to the spine starts with solving true unmet clinical needs and ends with creating a value-based solution for surgeons, patients, and the healthcare system. trans1.com/ifu MKT-52205.A
Overview
Location
United States, North Carolina, Wilmington
Employees
11-50
Phone
+1 888-526-1879
Total raised
$100.5M
Founded date
2015
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jul 26, 2007 | IPO | $80.5M |
Mentions in press and media 19
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 9, 2012 | Biolase CEO Pignatelli touts $1 salary | Earnings Roundup | Biolase Technology (NSDQ:BLTI) CEO Federico Pignatelli agreed to another year at a $1 salary as the dental laser maker met Wall Street’s 4th-quarter forecast with a whopping 35% top-line bump. Pignatelli set his annual pay package at $1 and... |
| Nov 2, 2011 | Volcano’s Q3 profits plunge 50 percent | Earnings Roundup | Volcano Corp. (NSDQ:VOLC) are down 4.4 percent this morning after the medical device company reported its third-quarter numbers yesterday, beating Wall Street’s expectations despite plunging profits, but lowering the top end of its sales gu... |
| Sep 27, 2011 | TranS1 lands $18 million through common stock offering | Lumbar spine surgery company TranS1 Inc. (NSDQ:TSON) raised $18.3 million of a hoped-for $20 million round through public sales of common stock. The Wilmington, N.C.-based company sold some 6.2 million shares at $3.25, according to SEC fili... |
| Sep 26, 2011 | Spinal surgery device firm TranS1 raises $18.3M in stock sale | Piper Jaffray & Co. acted as the sole book-running manager for the offering and Canaccord Genuity acted as co-manager. TranS1 granted to its underwriters a 30-day option to purchase an additional 930,000 shares of stock to cover any ove... |
| Sep 21, 2011 | TranS1 announces $20 million public stock offering for spinal surgery devices | Funding Roundup | Lumbar spine surgery company TranS1 Inc. (NSDQ:TSON) priced a public offering of 6.2 million shares of common stock at $3.25 per share, expecting to raise up to $20.2 million. TranS1 plans to use the funds for additional clinical trials, re... |
| Sep 21, 2011 | Medical device firm TranS1 prices stock offering; seeks $20M for clinical trials | TranS1 focuses on surgical devices that address degenerative spinal conditions that affect the lower lumbar region. The company said in securities filings that it will use net proceeds from the offering to finance additional clinical trials... |
| Aug 12, 2011 | Echo Therapeutics posts a tough quarter | Earnings Roundup | Echo Therapeutics Inc.’s (OTC:ECTE) grew more than three fold in Q2 as the company poured money into research & development and administrative expenses. Losses for the quarter widened 262 percent to $1.9 million, or a loss of 6 cents pe... |
| Feb 22, 2011 | Top device VC: Fix FDA or watch business go to Costa Rica | A Boston, Mass.-based venture capitalist and former Boston Scientific Corp. (NYSE:BSX) executive is adding his voice to the chorus of medical device stakeholders calling for an overhaul to the way the FDA regulates medical devices. In a col... |
| Feb 22, 2011 | FDA regulations will send medical device companies out of US, VC warns | LaViolette is no stranger to the device market or to the FDA’s Center for Devices & Radiological Health. He spent 15 years at the Natick, Mass.-based device giant, with stops as president of the cardiology and international groups. His ... |
Show more
Reviews 0
FAQ about TranS1
When was TranS1 founded?
TranS1 was founded in 2015.
How much funding has TranS1 raised?
TranS1 has raised $100.5M in total across 2 funding rounds.
What funding rounds has TranS1 raised?
Parsers VC lists 2 funding rounds of TranS1, among them an IPO of $80.5M on Jul 26, 2007.
What has the press written about TranS1?
Parsers VC has collected 19 articles mentioning TranS1, among them “Biolase CEO Pignatelli touts $1 salary | Earnings Roundup” (Mar 9, 2012) and “Volcano’s Q3 profits plunge 50 percent | Earnings Roundup” (Nov 2, 2011).
Is TranS1 still active?
Yes, TranS1 is active; its latest activity on Parsers VC dates from Mar 6, 2013.